Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Hedner

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Thrombosis and Haemostasis|February 1, 1994
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparinJ Holst, B Lindblad, D Bergqvist, et al.
Journal of Thrombosis and Haemostasis : JTH|December 1, 2009
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)R Gopalakrishnan, U Hedner, S Ghosh, et al.
Haemostasis|January 1, 1996
Experience with recombinant factor VIIa in Australia and New ZealandJ McPherson, L Teague, J Lloyd, et al.
Gastroenterology|December 12, 1997
Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary studyD E Bernstein, L Jeffers, E Erhardtsen, et al.
Circulation|August 5, 1997
Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primatesI B Sundell, U M Marzec, A B Kelly, et al.
The Journal of Trauma|April 17, 2001
Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuriesU Martinowitz, J B Holcomb, A E Pusateri, et al.
Haemostasis|January 1, 1996
Clinical experience with recombinant factor VIIa in patients with thrombocytopeniaJ Kristensen, A Killander, E Hippe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 13, 2009
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?E C Rodriguez-Merchan, U Hedner, L Heijnen, et al.
The Journal of Biological Chemistry|October 5, 1990
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactionsA H Pedersen, O Nordfang, F Norris, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 21, 2001
Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasisE Rodríguez-Iñigo, J Bartolomé, J A Quiroga, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Thrombosis and Haemostasis|February 1, 1994
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparinJ Holst, B Lindblad, D Bergqvist, et al.
Journal of Thrombosis and Haemostasis : JTH|December 1, 2009
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)R Gopalakrishnan, U Hedner, S Ghosh, et al.
Haemostasis|January 1, 1996
Experience with recombinant factor VIIa in Australia and New ZealandJ McPherson, L Teague, J Lloyd, et al.
Gastroenterology|December 12, 1997
Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary studyD E Bernstein, L Jeffers, E Erhardtsen, et al.
Circulation|August 5, 1997
Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primatesI B Sundell, U M Marzec, A B Kelly, et al.
The Journal of Trauma|April 17, 2001
Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuriesU Martinowitz, J B Holcomb, A E Pusateri, et al.
Haemostasis|January 1, 1996
Clinical experience with recombinant factor VIIa in patients with thrombocytopeniaJ Kristensen, A Killander, E Hippe, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 13, 2009
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?E C Rodriguez-Merchan, U Hedner, L Heijnen, et al.
The Journal of Biological Chemistry|October 5, 1990
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactionsA H Pedersen, O Nordfang, F Norris, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 21, 2001
Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasisE Rodríguez-Iñigo, J Bartolomé, J A Quiroga, et al.
Pageof 25